JP2022532991A5 - - Google Patents

Info

Publication number
JP2022532991A5
JP2022532991A5 JP2021563239A JP2021563239A JP2022532991A5 JP 2022532991 A5 JP2022532991 A5 JP 2022532991A5 JP 2021563239 A JP2021563239 A JP 2021563239A JP 2021563239 A JP2021563239 A JP 2021563239A JP 2022532991 A5 JP2022532991 A5 JP 2022532991A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021563239A
Other languages
English (en)
Japanese (ja)
Other versions
JP7695200B2 (ja
JP2022532991A (ja
Filing date
Publication date
Priority claimed from RU2019112296A external-priority patent/RU2734432C1/ru
Application filed filed Critical
Publication of JP2022532991A publication Critical patent/JP2022532991A/ja
Publication of JP2022532991A5 publication Critical patent/JP2022532991A5/ja
Application granted granted Critical
Publication of JP7695200B2 publication Critical patent/JP7695200B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021563239A 2019-04-23 2020-04-23 Gitrに特異的に結合するモノクローナル抗体 Active JP7695200B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU2019112296 2019-04-23
RU2019112296A RU2734432C1 (ru) 2019-04-23 2019-04-23 Моноклональное антитело, которое специфически связывается с GITR
PCT/RU2020/050080 WO2020218951A2 (ru) 2019-04-23 2020-04-23 Моноклональное антитело, которое специфически связывается с gitr

Publications (3)

Publication Number Publication Date
JP2022532991A JP2022532991A (ja) 2022-07-21
JP2022532991A5 true JP2022532991A5 (enExample) 2023-05-02
JP7695200B2 JP7695200B2 (ja) 2025-06-18

Family

ID=69821666

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021563239A Active JP7695200B2 (ja) 2019-04-23 2020-04-23 Gitrに特異的に結合するモノクローナル抗体

Country Status (24)

Country Link
US (1) US12410257B2 (enExample)
EP (1) EP3964525A4 (enExample)
JP (1) JP7695200B2 (enExample)
KR (1) KR20220010501A (enExample)
CN (1) CN110903392B (enExample)
AR (1) AR118763A1 (enExample)
AU (1) AU2020261207B2 (enExample)
BR (1) BR112021021281A2 (enExample)
CA (1) CA3137822A1 (enExample)
CL (1) CL2021002792A1 (enExample)
CO (1) CO2021014153A2 (enExample)
EA (1) EA202192907A1 (enExample)
IL (1) IL287531A (enExample)
JO (1) JOP20210286A1 (enExample)
MA (2) MA54969B2 (enExample)
MX (1) MX2021012962A (enExample)
MY (1) MY210018A (enExample)
PE (1) PE20220144A1 (enExample)
PY (1) PY2018606A (enExample)
RU (1) RU2734432C1 (enExample)
TW (1) TWI803718B (enExample)
UY (1) UY38672A (enExample)
WO (1) WO2020218951A2 (enExample)
ZA (1) ZA202109374B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2724470C1 (ru) * 2019-11-11 2020-06-23 Автономная некоммерческая образовательная организация высшего образования Сколковский институт науки и технологий Применение cas9 белка из бактерии pasteurella pneumotropica для модификации геномной днк в клетках
CN111732658B (zh) * 2020-06-28 2022-04-26 英诺湖医药(杭州)有限公司 一组gitr单克隆抗体及其医药用途
CN112362876B (zh) * 2020-08-06 2023-12-15 武汉天德生物科技有限公司 一种检测早期老年痴呆症的胶体金试纸条及其制备方法
CN112540179B (zh) * 2020-08-06 2023-07-07 武汉天德生物科技有限公司 一种测试ApoE4蛋白含量的ELISA试剂盒
CN111763257B (zh) * 2020-09-01 2020-12-15 北京百奥赛图基因生物技术有限公司 抗gitr抗体及其用途
CN112646040B (zh) * 2020-12-31 2022-03-25 中元汇吉生物技术股份有限公司 特异性结合人IgG4的蛋白及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
AU2004244626A1 (en) * 2003-05-23 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US20110123440A1 (en) 2005-03-29 2011-05-26 Genevieve Hansen Altered Antibody FC Regions and Uses Thereof
WO2007005612A2 (en) 2005-07-01 2007-01-11 Medimmune, Inc. An integrated approach for generating multidomain protein therapeutics
IN2015DN02826A (enExample) * 2009-09-03 2015-09-11 Merck Sharp & Dohme
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
LT3148579T (lt) 2014-05-28 2021-05-25 Agenus Inc. Anti-gitr antikūnai ir jų panaudojimo būdai
PL3151921T3 (pl) 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
SG11201705721WA (en) * 2015-01-14 2017-08-30 Brigham & Womens Hospital Inc Treatment of cancer with anti-lap monoclonal antibodies
EP3365371B1 (en) 2015-10-22 2025-10-08 Ablynx NV Gitr agonists
AU2016364895A1 (en) 2015-12-02 2018-06-07 Agenus Inc. Anti-GITR antibodies and methods of use thereof
CA3027121A1 (en) 2016-06-10 2017-12-14 Regeneron Pharmaceuticals, Inc. Anti-gitr antibodies and uses thereof
US20190263919A1 (en) 2016-07-01 2019-08-29 Five Prime Therapeutics, Inc. Combined anti tumor therapy with a gitr agonist and cpg
CA3033665A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
CA3042727A1 (en) * 2016-11-19 2018-05-24 Potenza Therapeutics, Inc. Anti-gitr antigen-binding proteins and methods of use thereof
WO2018145075A1 (en) 2017-02-06 2018-08-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for augmenting antibody mediated receptor signaling
US11198735B2 (en) * 2017-03-03 2021-12-14 Rinat Neuroscience Corp. Anti-GITR antibodies and methods of use thereof
TWI788340B (zh) * 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途

Similar Documents

Publication Publication Date Title
CN107151269B (zh) 一种pdl-1抗体、其药物组合物及其用途
KR20220110177A (ko) 항인간 클라우딘 18.2 항체 및 그의 적용
AU2020213579B2 (en) Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
JP2024075737A5 (enExample)
JP2019536430A5 (enExample)
CA3114467C (en) Anti pd-l1 antibody and use thereof
CN114181310A (zh) 抗tigit抗体、其药物组合物及用途
JP2024016024A5 (enExample)
EP4506360A1 (en) Anti-pvrig antibody, pharmaceutical composition thereof and use thereof
JP2023518153A5 (enExample)
WO2023241656A1 (zh) 包含抗cldn18.2抗体的双特异性抗体、药物组合物及用途
CN117679505A (zh) 药物组合及用途
JP2025514610A5 (enExample)
JP2024519078A5 (enExample)
JP2024540062A5 (enExample)
CN115850478A (zh) 抗cd20抗体或结合cd20的抗原结合片段及其应用
JP2024508597A5 (enExample)
CN113549152A (zh) 一种抗basigin人源化抗体及其应用
CN106963950B (zh) 用于治疗肿瘤的联合用药物
EP4678186A1 (en) Pharmaceutical composition comprising anti-ctla4-anti-pd-1 bispecific antibody and use thereof
HK40114665A (en) Pharmaceutical combination comprising an anti-ctla4-anti-pd-1 bispecific antibody and use thereof
WO2026061538A1 (zh) 用于治疗恶性肿瘤的抗pd-l1和抗4-1bb双特异性抗体及其药物组合
RU2021118025A (ru) Выделенное биспецифическое антитело, которое специфически связывается с CD47 и PD-L1
HK40089230A (en) Pharmaceutical composition and use
CN120623343A (zh) 一种b7-h6单克隆抗体及其应用